Loading…
Handling the different requirements for commercial and investigational MNC collections by apheresis
With the success of chimeric antigen receptor T-cell (CAR-T) and similar cellular-based therapies, the demand for collection of autologous mononuclear cells by apheresis (MNC(A)) from blood by apheresis has increased. From an apheresis technical standpoint, the collection of MNC(A) is relatively str...
Saved in:
Published in: | Cytotherapy (Oxford, England) England), 2024-08, Vol.26 (8), p.948-953 |
---|---|
Main Authors: | , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | cdi_FETCH-LOGICAL-c307t-c20b8c9bbb216ad62ff6b21588b925e40aa1399a0c3f58f88b56275fbbafad953 |
container_end_page | 953 |
container_issue | 8 |
container_start_page | 948 |
container_title | Cytotherapy (Oxford, England) |
container_volume | 26 |
creator | Bobr, Aleh Roberts, Timothy Koepsell, Scott Williams, Shelly M. Schwartz, Joseph |
description | With the success of chimeric antigen receptor T-cell (CAR-T) and similar cellular-based therapies, the demand for collection of autologous mononuclear cells by apheresis (MNC(A)) from blood by apheresis has increased. From an apheresis technical standpoint, the collection of MNC(A) is relatively straightforward, especially when compared with collection of hematopoietic progenitor cells (HPC(A)). Most of the collection for MNC(A) are performed for the commercial entities, who use the product for manufacturing cellular therapeutics. We have noticed discrepancies in the handling and apheresis processes required by different companies in obtaining essentially the same product (all companies in the study manufacture CAR-T-based products). We have analyzed the MNC collection requirements from all FDA-approved CAR-T cellular products and some investigational products collected at University of Nebraska Medical Center. We identified discrepancies in the process and suggested mitigation strategies.
Step-by-step analysis of the collection requirements. Review of the current guidelines and recommendations on this issue.
Multiple discrepancies in the collection process have been identified, even in the products collected for the same company. Practical approach of satisfying all the requirements based on University of Nebraska Medical Center experience has been suggested.
The current recommendations from multiple sources were reviewed in discussion. |
doi_str_mv | 10.1016/j.jcyt.2024.04.001 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3050942543</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1465324924005991</els_id><sourcerecordid>3050942543</sourcerecordid><originalsourceid>FETCH-LOGICAL-c307t-c20b8c9bbb216ad62ff6b21588b925e40aa1399a0c3f58f88b56275fbbafad953</originalsourceid><addsrcrecordid>eNp9UE1rGzEUFKElcd3-gR6Kjrms8ySttLvQSzFpE3DbS3IWkvbJltkPR1oH_O-jxW6OhQdvGGaG94aQrwxWDJi626_27jStOPByBXmAXZEFK6uq4FKpDzNWshC8bG7Ip5T2ABzqWl6TG1FXIJhUC-IezNB2YdjSaYe0Dd5jxGGiEV-OIWKfcaJ-jNSNfY_RBdPR7KBheMU0ha2Zwjhk7vefdZZ0HbqZSNSeqDnsclYK6TP56E2X8MtlL8nzz_un9UOx-fvrcf1jUzgB1VQ4DrZ2jbWWM2Vaxb1XGcq6tg2XWIIxTDSNASe8rH2mpeKV9NYab9pGiiW5Pece4vhyzOfpPiSHXWcGHI9JC5DQlFyWIkv5WerimFJErw8x9CaeNAM9l6v3ei5Xz-VqyAMsm75d8o-2x_bd8q_NLPh-FmD-8jVg1MkFHBy2uUo36XYM_8t_A9KTjRk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3050942543</pqid></control><display><type>article</type><title>Handling the different requirements for commercial and investigational MNC collections by apheresis</title><source>ScienceDirect Journals</source><creator>Bobr, Aleh ; Roberts, Timothy ; Koepsell, Scott ; Williams, Shelly M. ; Schwartz, Joseph</creator><creatorcontrib>Bobr, Aleh ; Roberts, Timothy ; Koepsell, Scott ; Williams, Shelly M. ; Schwartz, Joseph</creatorcontrib><description>With the success of chimeric antigen receptor T-cell (CAR-T) and similar cellular-based therapies, the demand for collection of autologous mononuclear cells by apheresis (MNC(A)) from blood by apheresis has increased. From an apheresis technical standpoint, the collection of MNC(A) is relatively straightforward, especially when compared with collection of hematopoietic progenitor cells (HPC(A)). Most of the collection for MNC(A) are performed for the commercial entities, who use the product for manufacturing cellular therapeutics. We have noticed discrepancies in the handling and apheresis processes required by different companies in obtaining essentially the same product (all companies in the study manufacture CAR-T-based products). We have analyzed the MNC collection requirements from all FDA-approved CAR-T cellular products and some investigational products collected at University of Nebraska Medical Center. We identified discrepancies in the process and suggested mitigation strategies.
Step-by-step analysis of the collection requirements. Review of the current guidelines and recommendations on this issue.
Multiple discrepancies in the collection process have been identified, even in the products collected for the same company. Practical approach of satisfying all the requirements based on University of Nebraska Medical Center experience has been suggested.
The current recommendations from multiple sources were reviewed in discussion.</description><identifier>ISSN: 1465-3249</identifier><identifier>ISSN: 1477-2566</identifier><identifier>EISSN: 1477-2566</identifier><identifier>DOI: 10.1016/j.jcyt.2024.04.001</identifier><identifier>PMID: 38703156</identifier><language>eng</language><publisher>England: Elsevier Inc</publisher><subject>apheresis ; MNC collection ; regulatory requirements</subject><ispartof>Cytotherapy (Oxford, England), 2024-08, Vol.26 (8), p.948-953</ispartof><rights>2024 International Society for Cell & Gene Therapy</rights><rights>Copyright © 2024 International Society for Cell & Gene Therapy. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c307t-c20b8c9bbb216ad62ff6b21588b925e40aa1399a0c3f58f88b56275fbbafad953</cites><orcidid>0000-0002-0398-2359 ; 0000-0003-1597-8071</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1465324924005991$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3548,27923,27924,45779</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38703156$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bobr, Aleh</creatorcontrib><creatorcontrib>Roberts, Timothy</creatorcontrib><creatorcontrib>Koepsell, Scott</creatorcontrib><creatorcontrib>Williams, Shelly M.</creatorcontrib><creatorcontrib>Schwartz, Joseph</creatorcontrib><title>Handling the different requirements for commercial and investigational MNC collections by apheresis</title><title>Cytotherapy (Oxford, England)</title><addtitle>Cytotherapy</addtitle><description>With the success of chimeric antigen receptor T-cell (CAR-T) and similar cellular-based therapies, the demand for collection of autologous mononuclear cells by apheresis (MNC(A)) from blood by apheresis has increased. From an apheresis technical standpoint, the collection of MNC(A) is relatively straightforward, especially when compared with collection of hematopoietic progenitor cells (HPC(A)). Most of the collection for MNC(A) are performed for the commercial entities, who use the product for manufacturing cellular therapeutics. We have noticed discrepancies in the handling and apheresis processes required by different companies in obtaining essentially the same product (all companies in the study manufacture CAR-T-based products). We have analyzed the MNC collection requirements from all FDA-approved CAR-T cellular products and some investigational products collected at University of Nebraska Medical Center. We identified discrepancies in the process and suggested mitigation strategies.
Step-by-step analysis of the collection requirements. Review of the current guidelines and recommendations on this issue.
Multiple discrepancies in the collection process have been identified, even in the products collected for the same company. Practical approach of satisfying all the requirements based on University of Nebraska Medical Center experience has been suggested.
The current recommendations from multiple sources were reviewed in discussion.</description><subject>apheresis</subject><subject>MNC collection</subject><subject>regulatory requirements</subject><issn>1465-3249</issn><issn>1477-2566</issn><issn>1477-2566</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNp9UE1rGzEUFKElcd3-gR6Kjrms8ySttLvQSzFpE3DbS3IWkvbJltkPR1oH_O-jxW6OhQdvGGaG94aQrwxWDJi626_27jStOPByBXmAXZEFK6uq4FKpDzNWshC8bG7Ip5T2ABzqWl6TG1FXIJhUC-IezNB2YdjSaYe0Dd5jxGGiEV-OIWKfcaJ-jNSNfY_RBdPR7KBheMU0ha2Zwjhk7vefdZZ0HbqZSNSeqDnsclYK6TP56E2X8MtlL8nzz_un9UOx-fvrcf1jUzgB1VQ4DrZ2jbWWM2Vaxb1XGcq6tg2XWIIxTDSNASe8rH2mpeKV9NYab9pGiiW5Pece4vhyzOfpPiSHXWcGHI9JC5DQlFyWIkv5WerimFJErw8x9CaeNAM9l6v3ei5Xz-VqyAMsm75d8o-2x_bd8q_NLPh-FmD-8jVg1MkFHBy2uUo36XYM_8t_A9KTjRk</recordid><startdate>20240801</startdate><enddate>20240801</enddate><creator>Bobr, Aleh</creator><creator>Roberts, Timothy</creator><creator>Koepsell, Scott</creator><creator>Williams, Shelly M.</creator><creator>Schwartz, Joseph</creator><general>Elsevier Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-0398-2359</orcidid><orcidid>https://orcid.org/0000-0003-1597-8071</orcidid></search><sort><creationdate>20240801</creationdate><title>Handling the different requirements for commercial and investigational MNC collections by apheresis</title><author>Bobr, Aleh ; Roberts, Timothy ; Koepsell, Scott ; Williams, Shelly M. ; Schwartz, Joseph</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c307t-c20b8c9bbb216ad62ff6b21588b925e40aa1399a0c3f58f88b56275fbbafad953</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>apheresis</topic><topic>MNC collection</topic><topic>regulatory requirements</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bobr, Aleh</creatorcontrib><creatorcontrib>Roberts, Timothy</creatorcontrib><creatorcontrib>Koepsell, Scott</creatorcontrib><creatorcontrib>Williams, Shelly M.</creatorcontrib><creatorcontrib>Schwartz, Joseph</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Cytotherapy (Oxford, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bobr, Aleh</au><au>Roberts, Timothy</au><au>Koepsell, Scott</au><au>Williams, Shelly M.</au><au>Schwartz, Joseph</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Handling the different requirements for commercial and investigational MNC collections by apheresis</atitle><jtitle>Cytotherapy (Oxford, England)</jtitle><addtitle>Cytotherapy</addtitle><date>2024-08-01</date><risdate>2024</risdate><volume>26</volume><issue>8</issue><spage>948</spage><epage>953</epage><pages>948-953</pages><issn>1465-3249</issn><issn>1477-2566</issn><eissn>1477-2566</eissn><abstract>With the success of chimeric antigen receptor T-cell (CAR-T) and similar cellular-based therapies, the demand for collection of autologous mononuclear cells by apheresis (MNC(A)) from blood by apheresis has increased. From an apheresis technical standpoint, the collection of MNC(A) is relatively straightforward, especially when compared with collection of hematopoietic progenitor cells (HPC(A)). Most of the collection for MNC(A) are performed for the commercial entities, who use the product for manufacturing cellular therapeutics. We have noticed discrepancies in the handling and apheresis processes required by different companies in obtaining essentially the same product (all companies in the study manufacture CAR-T-based products). We have analyzed the MNC collection requirements from all FDA-approved CAR-T cellular products and some investigational products collected at University of Nebraska Medical Center. We identified discrepancies in the process and suggested mitigation strategies.
Step-by-step analysis of the collection requirements. Review of the current guidelines and recommendations on this issue.
Multiple discrepancies in the collection process have been identified, even in the products collected for the same company. Practical approach of satisfying all the requirements based on University of Nebraska Medical Center experience has been suggested.
The current recommendations from multiple sources were reviewed in discussion.</abstract><cop>England</cop><pub>Elsevier Inc</pub><pmid>38703156</pmid><doi>10.1016/j.jcyt.2024.04.001</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0002-0398-2359</orcidid><orcidid>https://orcid.org/0000-0003-1597-8071</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1465-3249 |
ispartof | Cytotherapy (Oxford, England), 2024-08, Vol.26 (8), p.948-953 |
issn | 1465-3249 1477-2566 1477-2566 |
language | eng |
recordid | cdi_proquest_miscellaneous_3050942543 |
source | ScienceDirect Journals |
subjects | apheresis MNC collection regulatory requirements |
title | Handling the different requirements for commercial and investigational MNC collections by apheresis |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T07%3A39%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Handling%20the%20different%20requirements%20for%20commercial%20and%20investigational%20MNC%20collections%20by%20apheresis&rft.jtitle=Cytotherapy%20(Oxford,%20England)&rft.au=Bobr,%20Aleh&rft.date=2024-08-01&rft.volume=26&rft.issue=8&rft.spage=948&rft.epage=953&rft.pages=948-953&rft.issn=1465-3249&rft.eissn=1477-2566&rft_id=info:doi/10.1016/j.jcyt.2024.04.001&rft_dat=%3Cproquest_cross%3E3050942543%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c307t-c20b8c9bbb216ad62ff6b21588b925e40aa1399a0c3f58f88b56275fbbafad953%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3050942543&rft_id=info:pmid/38703156&rfr_iscdi=true |